Abstract: A dip tube (10) for extracting a fluid (102) from a bottle (104) comprises an adapter (12) configured to be at least partially inserted into a neck (106) of the bottle (104) and being provided with a connecting port (38) which is configured to be connected to a suction device (118), an elongated hollow withdrawal tube (14) which has a cross-sectional area that is smaller than a cross-sectional area of the adapter (12) and which is configured to protrude from the adapter (12) into a fluid receiving space (108) of the bottle (104), when the adapter (12) is inserted in the bottle neck (106), and which is arranged in fluid communication with the connecting port (38) of the adapter (12), and a sealing disc (52) extending from an outer circumferential surface (54) of the withdrawal tube (14) and being configured to abut against an inner surface (128) of the bottle (104) so as to seal the fluid receiving space (108) of the bottle (104).

Abstract: The present invention relates to a solid unit oral dosage form comprising sacubitril and valsartan in a 1:1 molar ratio, preferably in the form of the so-called angiotensin receptor neprilysin inhibitor (ARNI) LCZ696, which is a complex salt hydrate of sacubitril, valsartan, and sodium ions, appropriate for use in pediatrics or other patients where low and individual dosing is required or who encounter problems with swallowing e.g. as a result of a disease or because of age, to the manufacture of said solid dosage form and to invention embodiments relating to therapy using said dosage form.

Abstract: A dip tube (10) for extracting a fluid (102) from a bottle (104) comprises an adapter (12) configured to be at least partially inserted into a neck (106) of the bottle (104) and being provided with a connecting port (38) which is configured to be connected to a suction device (118), an elongated hollow withdrawal tube (14) which has a cross-sectional area that is smaller than a cross-sectional area of the adapter (12) and which is configured to protrude from the adapter (12) into a fluid receiving space (108) of the bottle (104), when the adapter (12) is inserted in the bottle neck (106), and which is arranged in fluid communication with the connecting port (38) of the adapter (12), and a sealing disc (52) extending from an outer circumferential surface (54) of the withdrawal tube (14) and being configured to abut against an inner surface (128) of the bottle (104) so as to seal the fluid receiving space (108) of the bottle (104).

Abstract: The present invention relates to a solid unit oral dosage form comprising sacubitril and valsartan in a 1:1 molar ratio, preferably in the form of the so-called angiotensin receptor neprilysin inhibitor (ARNI) LCZ696, which is a complex salt hydrate of sacubitril, valsartan, and sodium ions, appropriate for use in pediatrics or other patients where low and individual dosing is required or who encounter problems with swallowing e.g. as a result of a disease or because of age, to the manufacture of said solid dosage form and to invention embodiments relating to therapy using said dosage form.

Abstract: The present invention relates to methods and pharmaceutical compositions for treating heart failure in a pediatric human patient comprising administration to said patient of a therapeutically effective amount or a prophylactically effective amount of a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme, in particular of a combination of sacubitril and valsartan in a pharmaceutically acceptable form and in a 1:1 molar ratio.

Abstract: Methods of treating an SCD-mediated skin disorder or condition in a mammal, preferably a human, including administering to a mammal in need thereof a compound of formula (I): where x, y, W, V, R2, R3, R4, R5, R6, R6a, R7, R7a, R8, R8a, R9 and R9a are defined herein, and compositions including a compound of formula (I).

Abstract: The present invention relates to depot formulations comprising a poorly water soluble salt of a bisphosphonate forming together with one or more biocompatible polymers. The depot formulation may be in the form of microparticles or implants. The depot formulations are useful for the treatment and prevention of proliferative diseases including cancer.

Abstract: A process for purifying a polymer containing residual volatile monomers by drying the polymer powder under vacuum at a pressure and at a temperature which allows the vaporization of the residual monomers and optionally de-aggregating by sieving.

Abstract: A process for purifying a polymer containing residual volatile monomers by drying the polymer powder under vacuum at a pressure and at a temperature which allows the vaporization of the residual monomers and optionally de-aggregating by sieving.